Amended Securities Report – 78th Fiscal Period (2025/04/01 – 2026/03/31)

Ono Pharmaceutical Co., Ltd. Amended Securities Report – 78th Fiscal Period (2025/04/01 – 2026/03/31)

This report is an amended securities report submitted by Ono Pharmaceutical Co., Ltd. pursuant to the Financial Instruments and Exchange Act, containing financial and performance-related information for the 78th fiscal period (from April 1, 2025 to March 31, 2026). The filing of this report is necessitated by technical or accounting adjustments required in the previously submitted securities report, aiming to maintain corporate transparency and credibility.

Ono Pharmaceutical is primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products, including anticancer agents, central nervous system drugs, and immunosuppressants. Collaborating with medical institutions and pharmaceutical companies both domestically and internationally, the company is committed to delivering innovative medicines. This report details the revised financial figures such as net sales, operating income, and net profit, along with explanations for the revisions.

Additionally, the report includes information on corporate governance, executive remuneration, risk factors, and future outlook, serving as a critical document for investors, financial institutions, analysts, and other stakeholders to assess the company's financial health and sustainability.

The public disclosure of this report is expected to enhance the accuracy and consistency of market information, contributing to fair and efficient price formation.

Going forward, Ono Pharmaceutical will continue to uphold strict compliance with regulations and high standards of disclosure, striving for sustainable growth.